These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 20582732)
1. Prognostic and predictive biomarkers in renal cell carcinoma. Vickers MM; Heng DY Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732 [TBL] [Abstract][Full Text] [Related]
2. Current status and future directions of molecular markers in renal cell carcinoma. Rini BI Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in renal cell carcinoma]. Wen JJ; Zhou XJ Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112 [No Abstract] [Full Text] [Related]
4. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333 [TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812 [TBL] [Abstract][Full Text] [Related]
7. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476 [TBL] [Abstract][Full Text] [Related]
8. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134 [TBL] [Abstract][Full Text] [Related]
9. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710 [TBL] [Abstract][Full Text] [Related]
10. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736 [TBL] [Abstract][Full Text] [Related]
12. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin. Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319 [TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma. Rabjerg M Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890 [TBL] [Abstract][Full Text] [Related]
14. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Patard JJ; Fergelot P; Karakiewicz PI; Klatte T; Trinh QD; Rioux-Leclercq N; Said JW; Belldegrun AS; Pantuck AJ Int J Cancer; 2008 Jul; 123(2):395-400. PubMed ID: 18464292 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study. Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320 [TBL] [Abstract][Full Text] [Related]
16. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
17. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
18. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800 [TBL] [Abstract][Full Text] [Related]
19. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Cowey CL; Rathmell WK Curr Oncol Rep; 2009 Mar; 11(2):94-101. PubMed ID: 19216840 [TBL] [Abstract][Full Text] [Related]
20. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Golshayan AR; Brick AJ; Choueiri TK Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]